Seeking Alpha

Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete...

Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete response in an ongoing trial of a defactinib/ paclitaxel combo treatment. The patient's CA-125 level normalized after one cycle and "has remained at normal levels since," the company says. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)